paclitaxel has been researched along with Atypical Lipomatous Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aravantinos, G; Bafaloukos, D; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, C; Kosmidis, P; Linardou, H; Papadimitriou, C; Papakostas, P; Skarlos, D | 1 |
| Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Tsuruzoe, S; Yoshida, Y | 1 |
1 trial(s) available for paclitaxel and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Female; Histiocytoma, Benign Fibrous; Humans; Leiomyosarcoma; Liposarcoma; Liposomes; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Safety; Sarcoma; Survival Rate; Time Factors; Treatment Outcome | 2004 |
1 other study(ies) available for paclitaxel and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
[Weekly paclitaxel therapy is curative for patients with retroperitoneal liposarcoma].
Topics: Antineoplastic Agents, Phytogenic; Colectomy; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Liposarcoma; Middle Aged; Nephrectomy; Paclitaxel; Pelvic Neoplasms; Quality of Life; Retroperitoneal Neoplasms; Spleen | 2007 |